alexa Rosuvastatin And Olmesartan Improve Inflammation And Endothelial Dysfunction In Rheumatoid Arthritis
ISSN: 2329-6887

Journal of Pharmacovigilance
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

3rd International Conference and Exhibition on Pharmacovigilance & Clinical Trials
October 27-29, 2014 Hyderabad International Convention Centre, India

N Garg, A Syngle and P Krishan
Posters: J Pharmacovigilance
DOI: 10.4172/2329-6887.S1.014
Background: Cardiovascular disease remains the leading cause of excessive morbidity and mortality in Rheumatoid Arthritis (RA). Atherosclerosis and RA share similar pathogenetic mechanisms. Rosuvastatin and Olmesartan improve inflammation and endothelial dysfunction in non-rheumatic patients but it has not yet been investigated in rheumatic patients. Objective: To investigate the effects of rosuvastatin and olmesartan on inflammation and endothelial function in patients with rheumatoid arthritis. Methods: Forty five RA patients fulfilling the 2010 Rheumatoid Arthritis classification criteria were randomized into 3 groups to receive 6 months treatment with rosuvastatin (10 mg/day, n=15), olmesartan (10 mg/day, n=15) and placebo (n=15) as an adjunct to existing stable antirheumatic drugs. Flow mediated dilatation (FMD) was assessed by AngiodefenderTM (Everest Genomic Ann Arbor, United States). Inflammatory measures included Disease activity score of 28 joints (DAS28), CRP and ESR, pro-inflammatory cytokines (TNF-α, IL-6 and IL-1), serum nitrite and adhesion molecules (ICAM-1 and VCAM-1) and levels of lipids were measured at baseline and after treatment. Results: At baseline, all inflammatory measures, pro-inflammatory cytokines and adhesion molecules were elevated and endothelial function impaired among all the three groups. After 6 months of therapy, FMD increased by 67.1%, 44.1% and 6.1%, in the Rosuvastatin, Olmesartan and placebo groups respectively. DAS28 significantly reduced by 55.2%, 25% and 7.5%, in the rosuvastatin, olmesartan and placebo groups respectively. Both rosuvastatin and olmesartan significantly decreased serum CRP and TNF-α as compared with placebo. Rosuvastatin also significantly improved ESR, IL-6, ICAM-1and serum nitrite concentration after 6 months but olmesartan and placebo had no significant change in these measures. IL-1 showed insignificant changes in the both drug groups and placebo. Rosuvastatin produced significant reductions in total cholesterol and LDL cholesterol but there were no significant changes in the lipid profile in recipients of olmesartan and placebo. Olmesartan significantly reduced blood pressure compared with rosuvastatin and placebo. Significant negative correlation observed between FMD and IL-6 and TNF-α after treatment with rosuvastatin where as a significant inverse correlation was found between FMD and TNF-α after treatment with olmesartan. Conclusion: First study to show that Rosuvastatin and Olmesartan improve inflammation and endothelial dysfunction in RA. Both rosuvastatin and olmesartan lowers the pro-inflammatory cytokines especially IL-6 and TNF-α which down regulates the production of CRP and NO and improves the inflammation and endothelial dysfunction. However, Rosuvastatin in addition also favourably impacted ICAM-1 and lipid abnormalities. In contrast, olmesartan has beneficial effect on blood pressure. Thus both rosuvastatin and olmesartan have anti-inflammatory and vasculoprotective effects in RA mediated through antiproinflammatory cytokine action.
Nidhi Garg after B.Pharm had completed M.Pharmacy in pharmacy practice in 2008 and currently she is a doctoral research fellow in Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala. She has published more than 9 national and international publications in reputed journals and 18 national (IRACON) and international (EULAR, APLAR and ACR) conference proceedings. She also has two year teaching experience as a lecturer in pharmacy college. Last year she was invited for poster presentation on ?Nitric Oxide as a biomarker of disease activity and therapeutic response in Rheumatoid arthritis and Ankylosing Spondylitis? at ACCP 2013, Haiphong, Vietnam. Presently she is working on cardiovascular diseases, stem cells and effective therapy in rheumatic patients.
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

1-702-714-7001Extn: 9037

Business & Management Journals


1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version